The impact of FDA's warning on the use of antipsychotics in clinical practice: A survey

Consultant Pharmacist

Volumn 25, Issue 11, 2010, Pages 739-744

  Saad, Maha ^a   Cassagnol, Manouchkathe ^a   Ahmed, Ebtesam ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

Antipsychotics; Dementia; Elderly; Survey; Warnings

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL SUPERVISION; COMPUTER PROGRAM; DRUG CHOICE; DRUG CONTRAINDICATION; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; GERIATRICS; HEALTH CARE SURVEY; HUMAN; MEDICAL SPECIALIST; OUTCOME ASSESSMENT; PRESCRIPTION; PROFESSIONAL KNOWLEDGE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; WEBCAST; AGED; DEMENTIA; DRUG LABELING; STATISTICS; UNITED STATES;

AGED; ANTIPSYCHOTIC AGENTS; DEMENTIA; DRUG LABELING; HEALTH CARE SURVEYS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTIC DISORDERS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 79955790840     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2010.739     Document Type: Article

References (22)

1. Cohen-Mansfield J, Billing N. Agitated behaviors in the elderly. I: a conceptual review. J Am Geriatr Soc 1998;36:7-12.
2. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1154-66.
3. Lipercoti R, Mor B, Lapane KL et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003;64:1106-15.
4. Brodaty H, Ames D, Snowden et al. A randomized placebo controlled trial of risperidone for the treatment of aggression, agitation, and psychosis in dementia. J Clin Psychiatry 2003;64:134-43. (Pubitemid 36268315)
5. Wooltoron E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167:1269-70.
6. US Food and Drug Administration. RISPERDAL (risperidone) Dear Healthcare Professional Letter [Safety Alert]. Washington, DC: Department of Health and Human Services; 2004. Available at HYPERLINK "http://www.fda.gov/medwatch/ safety/2003/risperdal.htm" www.fda.gov/medwatch/safety/2003/risperdal.htm. Accessed February 22, 2010.
7. US Food and Drugs Administration. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances [Public Health Advisory]. Washington, DC: Department of Health and Human Services; www.fda.gov/Drugs/DrugSafety/ PublicHealthAdvisories/ucm053171.htm. Accessed March 8, 2010.
8. Gill SS, Bronskill SE, Normand SL et al. Antipsychotic drug use and death in older adults with dementia. Ann Intern Med 2007;146:775-86. (Pubitemid 351650498)
9. Schneeweiss S, Setoguchi S, Brookhart A et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007;176:627-32. (Pubitemid 46426056)
10. US Food and Drug Administration. Information for Healthcare Professionals: Conventional Antipsychotics [Safety Alert]. Washington, DC: Department of Health and Human Services; www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders.htm. Accessed March 8, 2010.
11. Southern California/RAND Evidence-based Practice Center. Agency for Healthcare Research and Quality (AHQR). US Department of Health and Human Services Executive Summary: Efficacy and Comparative Effectiveness of Off-Label Use of Atypical Antipsychotics. [Internet]. AHRQ Publication No. 07-EHC003-EF. January 2007. Available at www.effectivehealthcare.ahqr.gov/reports/final.cfm.
12. American Psychiatric Association (APA). Practice guideline for the treatment of patients with Alzheimer's disease and other dementias [Internet]. Arlington, VA: American Psychiatric Association (APA); October 2007:85 pp. Available at http://www.psychiatryonline.com/pracGuide/pracGuideTopic-3.aspx.
13. Salzman C, Jeste DV, Meyer RE et al. Elderly patients with dementia-related symptoms of severe agitation and aggression: consensus statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry 2008;69:889-98. (Pubitemid 351944940)
14. Chen Y, Briesacher BA, Field TS et al. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med 2010;170:89-95.
15. Kamble P, Sherer J, Chen H et al. Off-label use of second-generation antipsychotic agents among elderly nursing home residents. Psychiatr Serv 2010;61:130-6.
16. Rochon PA, Normand SL, Gomes T et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008;168:1090-6. (Pubitemid 351749226)
17. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38. (Pubitemid 44547805)
18. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43. (Pubitemid 41464695)
19. Rabins PV, Lyketsos CG. Antipsychotic drugs in dementia: what should be made of the risks? JAMA 2005;294:1963-5.
20. Dorsey ER, Rabbani A, Gallagher SA et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med 2010;170:96-103.
21. Rochon PA, Anderson GM. Prescribing optimal drug therapy for older people: sending the right message: comment on "impact of FDA black box advisory on antipsychotic medication use." Arch Intern Med 2010;170:103-6.
22. Kong EH, Evans LK, Guevara JP. Nonpharmacological intervention for agitation in dementia: a systematic review and meta-analysis. Aging Ment Health 2009;13:512-20.